Data from the National Inpatient Sample show that the decrease in hospitalizations related to methicillin-resistant Staphylococcus aureus (MRSA) infections between 2010 and 2014 primarily reflected declines in skin and soft tissue infections. Hospitalizations related to invasive MRSA remained largely unchanged.
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Methicillin-resistant Staphylococcus aureus (MRSA) is the leading cause of mortality due to antibiotic-resistant infections in the United States [1] . The emergence of community-associated MRSA, notably the USA300 strain, in the late 1990s led to a large increase in the number of hospitalizations for MRSA, driven mainly by skin and soft tissue infections (SSTIs) [2] . Recent reports suggest that overall rates of invasive MRSA infections have dropped significantly from a peak in 2005 [3] . However, national trends in MRSA-related hospitalizations have not been reported since 2009 [4] . In this study, we estimate the rate of MRSA-related hospitalizations in the United States from 2010 to 2014.
METHODS
We calculated rates of S. aureus-and MRSA-related hospitalizations from 2010 to 2014 using the National Inpatient Sample (NIS) from the Healthcare Cost and Utilization Project of the Agency for Health Research and Quality. The NIS includes >7 million inpatient records sampled from nonfederal hospitals in the United States. Each record is weighted to produce national estimates of hospitalization and contains up to 25 discharge diagnoses, which are classified using the International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM). MRSA-specific codes were added as possible discharge diagnoses in October 2008.
All records containing ≥1 S. aureus or MRSA infection code were included: septicemia (038.11, 038.12), pneumonia (482.41, 482.42), and conditions classified elsewhere and of unspecified site (041.11, 041.12). Records with multiple S. aureus infection codes were counted only once, with preference given to septicemia, followed by pneumonia and then other codes. Hospitalization rates were calculated by dividing the number of S. aureus-and MRSA-related hospitalizations by the total number of hospitalizations. Because 041 codes are intended to be secondary, we examined the primary diagnoses associated with these infections. Deaths were attributed only for hospitalizations in which the primary diagnosis code was an S. aureus code. A χ 2 test for linear trend was used to determine whether the results for each diagnosis exhibited a trend over time, and the adjusted Wald test was used to determine statistically significant differences in hospitalization rates between 2010 and 2014. All analyses were performed using Stata 14 software (StataCorp) and took into account the complex sampling design of the NIS.
RESULTS
The , and the rate of MSSA-related hospitalizations increased from 6.39 (6.17-6.62) to 7.27 (7.14-7.39; difference, P < .001; trend, P = .007). MRSA-related hospitalizations fell in all census regions. The largest decrease was in the South, although rates there remained higher than in other regions (Supplementary Figure S1 and Supplementary Table S1 ).
The decline in MRSA-related hospitalizations was primarily attributable to a decrease in unspecified MRSA-related infections, which fell from 8.32 (95% CI, 8.01-8.62) to 7.17 (7.04-7.30; difference, P < .001; trend. P = .01) per 1000 hospitalizations. MRSA-related pneumonia infections decreased as well, although only between 2013 and 2014, accounting for only 13% of the overall decrease, falling from 1.54 (95% CI, 1.44-1.64) per 1000 hospitalizations to 1.38 (1.32-1.43; difference, P = .004; trend, P = .19). The rate of MRSA-related septicemia hospitalizations increased slightly, from 1.45 (95% CI, 1.38-1.52) to 1.53 (1.49-1.58; difference, P = .04; trend, P = .78) per 1000 hospitalizations, and the rate of MSSA-related septicemia increased from 1.21 (1.16-1.27) to 1.61 (1.57-1.66; difference, P < .001; trend, P = .007) per 1000 hospitalizations. Regionally, the South had the highest rates for each infection type, and similar to national data, experienced the largest decrease in unspecified MRSA-related infections (Supplementary Figure S2) .
The most frequent primary diagnoses associated with "other" MRSA-related infections were cellulitis and abscess infections (ICD-9-CM codes 680-686). Rates of hospitalization for MRSA-related SSTIs decreased 29%, from 3.8 (95% CI, 3.6-4.0) to 3.0 (2.9-3.1) per 1000 hospitalizations between 2010 and 2014. Hospitalization rates for other common primary diagnoses associated with unspecified MRSA-related infections (eg, implanted device or graft, diabetes mellitus, and postoperative infection), did not change greatly during the study period (Supplementary Figure S3) .
MRSA-and MSSA-related mortality rates did not change significantly over the 4-year period. In 2014, the MRSA-and MSSA-related mortality rates were 0.14 (95% CI, .13-.15) and 0.11 (.10-.11) deaths per 1000 hospitalizations, respectively, with an estimated 5090 (95% CI, 4670-5520) MRSA-related and 3755 (3559-3955) MSSA-related deaths.
DISCUSSION
Hospitalization rates for MRSA-related SSTIs decreased between 2010 and 2014 while rates for more invasive MRSArelated infections-sepsis-remained largely constant. These results contrast with reported reductions in the incidence of invasive MRSA and hospital-onset MRSA bacteremia from the US Centers for Disease Control (CDC) Active Bacterial Core surveillance (ABCs) system [3] and National Healthcare Safety Network (NHSN) [5] . The ABCs system, which covers 9 US metropolitan areas, reported significant reductions in the incidence of invasive MRSA infections between 2005 and 2011 [3] , while NHSN reported a 13% decrease in hospital-onset MRSA bacteremia between 2011 and 2014 [5] . However, although the ABCs system reported further large reductions in 2012, incidence rates plateaued in 2013 and 2014 [6] [7] [8] .
These differences may be because NHSN measures hospital-onset infections and not community-associated infections, and increased screening may have led to changes in onset classification without changing rates of infection. The study populations differ for the ABCs system as well, which includes outpatient settings, whereas the current study included only hospitalized patients. There are geographic differences as well, because the ABCs system includes only selected counties in 9 states and is weighted toward urban areas, and MRSA may differ epidemiologically in areas not covered. For instance, reports have shown an increase in MRSArelated pneumonia in areas not included in the ABCs system over a similar time period [9] . In addition, the definition of invasive MRSA used in the ABCs system may not completely overlap with the ICD-9-CM sepsis codes used in the current study. Finally, studies have demonstrated changes in coding practices that may have increased the probability of documenting MRSA-related sepsis, leading to an appearance of stability even if the rate of MRSArelated sepsis was actually decreasing.
The introduction of an MRSA-specific ICD-9-CM code in 2008 allows for improved surveillance capability. Caution is required in using these codes because no study of their validity has been conducted. However, our results are consistent with prior reports that used alternative methods [4] and are similar in magnitude to national estimates from the CDC [3] . In addition, although poor specificity in prior MRSA codes has been documented [10] , the newer MRSA codes are similar to S. aureus codes that have been shown to be highly predictive of S. aureus sepsis infections in the past [11] .
Consistent with prior reports [12] , we found that rates of MRSA were higher in the South than in other regions. This may be due to warmer weather, which has been associated with higher rates of MRSA, particularly community-associated MRSA [13] . Rates of MRSA-related compared with MSSASSTIs were highest in this region as well (Supplementary Figure  S2) , further suggesting that climatic factors may be driving this epidemic. Alternatively, rates of outpatient antibiotic use are highest in the South [14] which may contribute to higher rates of MRSA-related SSTIs and hospitalizations.
The decrease in rates of noninvasive MRSA hospitalizations may be attributable to a combination of efforts to combat this public health crisis. However, because the decrease was largely confined to community-associated infections, these changes may instead reflect the natural waning of an epidemic. Despite the decreasing trend, rates of MRSA remain higher in the United States than in most other developed countries, particularly for invasive sepsis and pneumonia infections, which are often healthcare associated. Future policies should focus on increasing infection prevention efforts, which have demonstrated efficacy in reducing long-term incidence of MRSA at the hospital level [15] and would help avoid all S. aureus infections. In addition, national targets and coordinated policies at the regional level should be implemented, but additional resources are needed to facilitate these activities.
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